- mehrmals pro WocheErscheinungsrhythmus
- 50 mintypische Länge
- vor 2 Tagenletzte Folge
Featuring one-on-one interviews conducted by Dr Neil Love, this series provides medical oncologists with access to an array of important perspectives and information on relevant advances in the treatment of hematologic cancer to facilitate optimal patient care.
Folgen
Novel Therapies for Non-Hodgkin Lymphoma — Microlearning Activity 1: An Interview with Dr Matthew Lunning on CNS Prophylaxis
Featuring an interview with Dr Matthew Lunning, including the following topics: • A woman in her late 70s with non-GCB diffuse large B-cell lymphoma receives pola-R-CHP — Ann LaCasce, MD, MMSc (0:00) • CNS prophylaxis in non-Hodgkin lymphom
Chronic Lymphocytic Leukemia — Rapid Case Review: Microlearning Activity 6
Featuring perspectives from Dr Lindsey Roeker, including the following topics: • Case: A man in his mid 60s with TP53-aberrant chronic lymphocytic leukemia (CLL) with extensive marrow infiltration receives first-line venetoclax/obinutuzumab
Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 5
Featuring perspectives from Dr Lindsey Roeker, including the following topics: • Consensus Approach to optimizing front-line treatment (0:00) • Emerging role of sonrotoclax (8:39) • Bruton tyrosine kinase inhibitor monotherapy for older pat
Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome
Featuring perspectives from Dr Spencer Bachow, Dr Bhavana (Tina) Bhatnagar, Dr Jennifer Crombie, Dr Manali Kamdar and Ms Alexandra Lynch, co-moderated by Dr Bachow and Dr Bhatnagar, including the following topics: • Introduction and Overvie
Chronic Lymphocytic Leukemia — Microlearning Activity 2
Featuring perspectives from Dr Catherine C Coombs, including the following topics: • Phase III BRUIN CLL-322 trial of fixed-duration pirtobrutinib in combination with venetoclax and rituximab for previously treated chronic lymphocytic leuke
Chronic Lymphocytic Leukemia — Microlearning Activity 1
Featuring perspectives from Dr Catherine C Coombs, including the following topics: • Early versus delayed addition of obinutuzumab to acalabrutinib and venetoclax in treatment-naïve chronic lymphocytic leukemia (CLL) (0:00) • Feasibility of
Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2026 Annual Meeting
Featuring perspectives from Dr Meletios-Athanasios (Thanos) C Dimopoulos, Dr Robert Z Orlowski and Dr Noopur Raje, moderated by Dr Orlowski, including the following topics: • Introduction (0:00) • New and Emerging Strategies with Bispecific
Chronic Lymphocytic Leukemia — Investigators Discuss Optimal Management
Featuring perspectives from Dr Catherine C Coombs and Dr Matthew S Davids, including the following topics: • Introduction (0:00) • Minimal Residual Disease Assays in Community-Based Practice (1:24) • New Developments in Previously Untreated
Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies
Featuring an interview with Dr L Elizabeth Budde, including the following topics: • Considerations for selecting between bispecific antibodies (BsAbs); monotherapy versus combination therapy (0:00) • Management of BsAb-induced cytokine rele
Diffuse Large B-Cell Lymphoma — Proceedings from a Symposium Held in Conjunction with the American Oncology Network
Featuring perspectives from Dr Ann LaCasce and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics: • Introduction (0:00) • First-Line Treatment (1:33) • Bispecific Antibodies and Chimeric Antigen Receptor T-Cel
Chronic Lymphocytic Leukemia — Proceedings from a Symposium Held in Conjunction with the American Oncology Network
Featuring perspectives from Dr Farrukh T Awan and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics: • Introduction (0:00) • First-Line Therapy (2:48) • Relapsed/Refractory Disease (39:30) CME information and
Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia — Reviewing Recent Datasets from the 2026 ASCO Annual Meeting and EHA2026 Congress
Featuring perspectives from Dr Brad S Kahl, Dr Jeff Sharman and Dr Tanya Siddiqi, including the following topics: • Introduction (0:00) • Trials in Progress (1:12) • Chronic Lymphocytic Leukemia (7:09) • Diffuse Large B-Cell Lymphoma (32:35
Antibody-Drug Conjugates for Multiple Myeloma — An Interview with Dr Douglas W Sborov
Featuring an interview with Dr Douglas W Sborov, including the following topics: • DREAMM-2 trial outcomes and clinical development of antibody-drug conjugates for multiple myeloma (MM); mechanism of action of belantamab mafodotin (belamaf)
Chronic Myeloid Leukemia — An Interview with Prof Andreas Hochhaus
Featuring an interview with Prof Andreas Hochhaus, including the following topics: • Biology of chronic myeloid leukemia (CML) and rationale for current therapeutic approaches; importance of cytogenetic testing (0:00) • Mechanistic differen
Chronic Lymphocytic Leukemia — Rapid Case Review: Microlearning Activity 4
Featuring perspectives from Prof John Seymour and cases from Dr Daniel Ermann, Dr Shazia Nakhoda and Dr Mahesh Swaminathan, including the following topics: • Case: A woman in her mid 50s with multiple sclerosis, hypertension, IGHV-unmutated
Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 3
Featuring perspectives from Prof John Seymour, including the following topics: • Safety of fixed-duration acalabrutinib/venetoclax for chronic lymphocytic leukemia (CLL) (0:00) • Venetoclax re-treatment and ongoing trials with acalabrutinib
Relapsed/Refractory Chronic Lymphocytic Leukemia — A Grand Rounds Program
Featuring perspectives from Dr William G Wierda, including the following topics: • Introduction: Overview of the Grand Rounds Chronic Lymphocytic Leukemia Initiative (0:00) • Sequencing Road Map (12:39) • Key Datasets — Pirtobrutinib (21:08
Non-Hodgkin Lymphoma — Year in Review Series on Relevant New Datasets and Advances
Featuring perspectives from Dr Matthew Matasar and Dr Sonali M Smith, including the following topics: • Introduction: Lymphoma Survivorship (0:00) • Novel Treatment Approaches for Diffuse Large B-Cell Lymphoma — Dr Matasar (6:49) • Novel Tr
Multiple Myeloma — Year in Review Series on Relevant New Datasets and Advances
Featuring perspectives from Dr Amrita Krishnan and Dr Robert Z Orlowski, including the following topics: • Introduction (00:00) • Up-Front Progression-Free Survival for Standard-Risk Disease — 2006, 2016 (1:47) • Current and Emerging Therap
Non-Hodgkin Lymphoma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting on the Roles of CAR T-Cell Therapy and Bispecific Antibodies
Featuring perspectives from Dr Jeremy S Abramson, Dr Joshua Brody, Dr Manali Kamdar, Dr Tycel Phillips and Dr Jason Westin, moderated by Dr Abramson, including the following topics: • Introduction (0:00) • Chimeric Antigen Receptor (CAR) T-
Myelofibrosis — Proceedings from a Webinar Held in Conjunction with the 2026 ASCO Annual Meeting
Featuring perspectives from Prof Claire Harrison and Dr Raajit K Rampal, including the following topics: • Introduction (0:00) • The Biopathophysiology of Myelofibrosis (MF) (2:19) • Current and Future Clinical Decision-Making in the Absenc
Chronic Lymphocytic Leukemia — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
Featuring perspectives from Dr Jeremy S Abramson, Dr John N Allan, Dr Bita Fakhri, Dr Shuo Ma and Dr Mazyar Shadman, moderated by Dr Abramson, including the following topics: • Introduction (0:00) • Current and Future Role of Continuous Bru
For Oncology Nurses: Relapsed/Refractory Multiple Myeloma — Proceedings from the 2026 Annual ONS Congress
Featuring perspectives from Dr Beth Faiman, Dr Natalie S Callander, Dr Hans Lee and Dr Mary Steinbach, moderated by Dr Callander, including the following topics: • Introduction (00:00) • Role of Chimeric Antigen Receptor T-Cell Therapy in R
Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 1
Featuring perspectives from Dr Mazyar Shadman, including the following topics: • The CLL17 trial: Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia (CLL) (0:00) • The AMPLIFY trial: Fi
Chronic Lymphocytic Leukemia — Rapid Case Review: Microlearning Activity 2
Featuring perspectives from Dr Mazyar Shadman and cases from Dr Daniel Ermann, Dr Shazia Nakhoda and Dr Mahesh Swaminathan, including the following topics: • Case: A man in his mid 40s with chronic lymphocytic leukemia (CLL) receives acalab
Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
Featuring perspectives from Dr Melissa Alsina, Dr Hans Lee, Dr Sagar Lonial and Dr Paul G Richardson, moderated by Dr Lonial, including the following topics: • Introduction (0:00) • Integrating Bispecific Antibodies into the Management of R
For Oncology Nurses: Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia — Proceedings from the 2026 Annual ONS Congress
Featuring perspectives from Dr Farrukh T Awan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran, moderated by Dr Kahl, including the following topics: • Introduction: Biology of Non-Hodgkin Lymphoma (NHL) (00:00) • Current Role of CD20 x
Novel Therapies for Non-Hodgkin Lymphoma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
Featuring perspectives from Dr Christopher Flowers, Dr Matthew Lunning, Dr Sonali M Smith and Dr Brad S Kahl, moderated by Dr Kahl, including the following topics: • Rational Incorporation of CD79b-Targeted Antibody-Drug Conjugates into the
Acute Myeloid Leukemia — Fifth Annual National General Medical Oncology Summit
Featuring perspectives from Dr Courtney D DiNardo and Dr Harry Paul Erba, including the following topics: • Introduction (0:00) • Current Management Approaches for FLT3- and IDH-Mutated Acute Myeloid Leukemia (AML) — Dr DiNardo (9:44) • Cur
Myelofibrosis and Systemic Mastocytosis — Fifth Annual National General Medical Oncology Summit
Featuring perspectives from Dr Anthony M Hunter and Dr Abdulraheem Yacoub, including the following topics: • Introduction (0:00) • Systemic Mastocytosis — Dr Hunter (9:33) • Myelofibrosis — Dr Yacoub (29:40) CME information and select publi
